Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 3Phase EARLY_PHASE1 2Phase 1 2Phase 3 1

Status

Completed 15Terminated 2Withdrawn 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1CNS 1

Conditions

Recurrence 1Neuroblastoma 1Neoplasms 1

Interventions

Cyclophosphamide 98pembrolizumab 87Gemcitabine 81Carboplatin 63fludarabine 62Nivolumab 57Cisplatin 54Paclitaxel 51Radiotherapy 50Docetaxel 50Rituximab 46Dexamethasone 42Lenalidomide 41Ipilimumab 38Azacitidine 35Etoposide 34Cytarabine 34Temozolomide 32Bevacizumab 32Radiation 29venetoclax 28Bortezomib 27Magnetic Resonance Spectroscopy 26Irinotecan 26atezolizumab 25Pemetrexed 25Oxaliplatin 24Capecitabine 24fludarabine phosphate 23Filgrastim 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Terminated × Ketoconazole × Clear all
NCT02163356 2022-03-31

SPOC2013-001

South Plains Oncology Consortium

Phase 1 Terminated
4 enrolled
CNS

Neuroblastoma, Recurrence

NCT00162214 2011-04-14

Study of Dasatinib in Patients With Advanced Solid Tumors

Bristol-Myers Squibb

Phase 1 Terminated
60 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡